Tislelizumab-jsgr
HealthData.Gov
Updated Mar 24, 2026
About this dataset
TEVIMBRA (tislelizumab-jsgr) is an intravenous injection used as an immunotherapy drug that blocks programmed death receptor-1 (PD-1) to help the immune system fight certain cancers. Manufactured by BeOne Medicines USA, Inc., it's available as a 10 mg/mL solution concentrate, approved under BLA761232 and marketed since March 2024. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Tislelizumab-jsgr
Access the FDA dataset for Tislelizumab-jsgr β ANDA 203308 submitted by Mylan Institutional LLC
Modified Dec 27, 2025